Annual FCF
-$23.38 M
+$49.88 M+68.08%
31 December 2023
Summary:
Akebia Therapeutics annual free cash flow is currently -$23.38 million, with the most recent change of +$49.88 million (+68.08%) on 31 December 2023. During the last 3 years, it has risen by +$87.32 million (+78.88%). AKBA annual FCF is now -142.33% below its all-time high of $55.24 million, reached on 31 December 2016.AKBA Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$6.70 M
+$3.40 M+33.66%
30 September 2024
Summary:
Akebia Therapeutics quarterly free cash flow is currently -$6.70 million, with the most recent change of +$3.40 million (+33.66%) on 30 September 2024. Over the past year, it has increased by +$470.00 thousand (+6.56%). AKBA quarterly FCF is now -107.00% below its all-time high of $95.62 million, reached on 31 December 2016.AKBA Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$38.53 M
+$470.00 K+1.21%
30 September 2024
Summary:
Akebia Therapeutics TTM free cash flow is currently -$38.53 million, with the most recent change of +$470.00 thousand (+1.21%) on 30 September 2024. Over the past year, it has increased by +$37.22 million (+49.14%). AKBA TTM FCF is now -147.93% below its all-time high of $80.38 million, reached on 30 June 2017.AKBA TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AKBA Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +68.1% | +6.6% | +49.1% |
| 3 y3 years | +78.9% | +88.1% | +82.6% |
| 5 y5 years | +76.4% | -179.2% | +84.3% |
AKBA Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +90.8% | -119.8% | +89.3% | -64.8% | +84.8% |
| 5 y | 5 years | at high | +91.2% | -118.0% | +92.8% | -64.8% | +85.4% |
| alltime | all time | -142.3% | +91.2% | -107.0% | +95.2% | -147.9% | +85.6% |
Akebia Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$6.70 M(-33.7%) | -$38.53 M(-1.2%) |
| June 2024 | - | -$10.10 M(-48.0%) | -$39.00 M(+54.3%) |
| Mar 2024 | - | -$19.43 M(+741.9%) | -$25.28 M(+8.1%) |
| Dec 2023 | -$23.38 M(-68.1%) | -$2.31 M(-67.8%) | -$23.38 M(-69.1%) |
| Sept 2023 | - | -$7.17 M(-297.5%) | -$75.75 M(+117.8%) |
| June 2023 | - | $3.63 M(-120.7%) | -$34.78 M(-49.6%) |
| Mar 2023 | - | -$17.54 M(-67.9%) | -$69.07 M(-5.7%) |
| Dec 2022 | -$73.27 M(-71.0%) | -$54.68 M(-261.7%) | -$73.27 M(-10.0%) |
| Sept 2022 | - | $33.80 M(-210.3%) | -$81.40 M(-52.5%) |
| June 2022 | - | -$30.66 M(+41.1%) | -$171.47 M(-15.9%) |
| Mar 2022 | - | -$21.73 M(-65.4%) | -$203.95 M(-19.4%) |
| Dec 2021 | -$253.02 M(+128.6%) | -$62.81 M(+11.6%) | -$253.02 M(+14.3%) |
| Sept 2021 | - | -$56.27 M(-10.9%) | -$221.31 M(+15.1%) |
| June 2021 | - | -$63.14 M(-10.8%) | -$192.24 M(+109.1%) |
| Mar 2021 | - | -$70.81 M(+127.7%) | -$91.92 M(-17.0%) |
| Dec 2020 | -$110.70 M(-58.1%) | -$31.10 M(+14.4%) | -$110.70 M(-35.6%) |
| Sept 2020 | - | -$27.19 M(-173.1%) | -$171.96 M(+26.2%) |
| June 2020 | - | $37.17 M(-141.5%) | -$136.31 M(-36.3%) |
| Mar 2020 | - | -$89.59 M(-3.0%) | -$213.83 M(-19.0%) |
| Dec 2019 | -$264.10 M(+166.5%) | -$92.36 M(-1191.7%) | -$264.10 M(+7.2%) |
| Sept 2019 | - | $8.46 M(-121.0%) | -$246.27 M(-7.9%) |
| June 2019 | - | -$40.34 M(-71.2%) | -$267.50 M(+22.5%) |
| Mar 2019 | - | -$139.86 M(+87.7%) | -$218.33 M(+120.3%) |
| Dec 2018 | -$99.10 M | -$74.53 M(+483.7%) | -$99.10 M(+139.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$12.77 M(-244.7%) | -$41.40 M(-50.6%) |
| June 2018 | - | $8.82 M(-142.8%) | -$83.84 M(+22.5%) |
| Mar 2018 | - | -$20.63 M(+22.6%) | -$68.45 M(+18.5%) |
| Dec 2017 | -$57.78 M(-204.6%) | -$16.83 M(-69.5%) | -$57.78 M(-205.7%) |
| Sept 2017 | - | -$55.21 M(-328.0%) | $54.67 M(-32.0%) |
| June 2017 | - | $24.22 M(-343.3%) | $80.38 M(+187.5%) |
| Mar 2017 | - | -$9.96 M(-110.4%) | $27.96 M(-49.4%) |
| Dec 2016 | $55.24 M(-204.6%) | $95.62 M(-424.2%) | $55.24 M(-187.2%) |
| Sept 2016 | - | -$29.50 M(+4.6%) | -$63.36 M(+47.3%) |
| June 2016 | - | -$28.20 M(-262.8%) | -$43.01 M(+59.6%) |
| Mar 2016 | - | $17.32 M(-175.4%) | -$26.95 M(-49.0%) |
| Dec 2015 | -$52.82 M(+90.6%) | -$22.98 M(+151.3%) | -$52.82 M(+35.2%) |
| Sept 2015 | - | -$9.15 M(-24.7%) | -$39.06 M(+9.9%) |
| June 2015 | - | -$12.14 M(+42.1%) | -$35.55 M(+18.1%) |
| Mar 2015 | - | -$8.55 M(-7.3%) | -$30.11 M(+8.6%) |
| Dec 2014 | -$27.71 M(+144.1%) | -$9.22 M(+63.5%) | -$27.71 M(+18.4%) |
| Sept 2014 | - | -$5.64 M(-15.8%) | -$23.41 M(+13.0%) |
| June 2014 | - | -$6.70 M(+8.9%) | -$20.71 M(+29.7%) |
| Mar 2014 | - | -$6.15 M(+25.0%) | -$15.97 M(+40.7%) |
| Dec 2013 | -$11.35 M(+57.4%) | -$4.92 M(+67.2%) | -$11.35 M(+76.5%) |
| Sept 2013 | - | -$2.94 M(+50.4%) | -$6.43 M(+84.4%) |
| June 2013 | - | -$1.96 M(+27.9%) | -$3.49 M(+127.9%) |
| Mar 2013 | - | -$1.53 M | -$1.53 M |
| Dec 2012 | -$7.21 M | - | - |
FAQ
- What is Akebia Therapeutics annual free cash flow?
- What is the all time high annual FCF for Akebia Therapeutics?
- What is Akebia Therapeutics annual FCF year-on-year change?
- What is Akebia Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Akebia Therapeutics?
- What is Akebia Therapeutics quarterly FCF year-on-year change?
- What is Akebia Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Akebia Therapeutics?
- What is Akebia Therapeutics TTM FCF year-on-year change?
What is Akebia Therapeutics annual free cash flow?
The current annual FCF of AKBA is -$23.38 M
What is the all time high annual FCF for Akebia Therapeutics?
Akebia Therapeutics all-time high annual free cash flow is $55.24 M
What is Akebia Therapeutics annual FCF year-on-year change?
Over the past year, AKBA annual free cash flow has changed by +$49.88 M (+68.08%)
What is Akebia Therapeutics quarterly free cash flow?
The current quarterly FCF of AKBA is -$6.70 M
What is the all time high quarterly FCF for Akebia Therapeutics?
Akebia Therapeutics all-time high quarterly free cash flow is $95.62 M
What is Akebia Therapeutics quarterly FCF year-on-year change?
Over the past year, AKBA quarterly free cash flow has changed by +$470.00 K (+6.56%)
What is Akebia Therapeutics TTM free cash flow?
The current TTM FCF of AKBA is -$38.53 M
What is the all time high TTM FCF for Akebia Therapeutics?
Akebia Therapeutics all-time high TTM free cash flow is $80.38 M
What is Akebia Therapeutics TTM FCF year-on-year change?
Over the past year, AKBA TTM free cash flow has changed by +$37.22 M (+49.14%)